Literature DB >> 30558519

Discrete Perineural Invasion Focus Number in Quantification for T1-T2 Oral Squamous Cell Carcinoma.

Pei-Yin Wei1, Wing-Yin Li2, Shyh-Kuan Tai1,3,4.   

Abstract

OBJECTIVE: Perineural invasion (PNI) has been an established poor prognostic feature for T1-T2 oral squamous cell carcinoma (OSCC). Different presentations and amounts of PNI are commonly observed, but PNI is currently recorded as being present or absent. This study asked whether the quantification of PNI provides additional information for early OSCC. STUDY
DESIGN: Retrospective cohort study.
SETTING: Tertiary referral medical center. SUBJECTS AND METHODS: Pathologic reevaluations were performed for 314 patients with T1-T2 OSCC who underwent curative surgery from June 2001 to August 2009. A novel parameter, PNI focus number, was defined for PNI quantification. With 5 PNI foci as the cutoff, patients were categorized into 3 groups: no PNI (0 PNI foci), low PNI (PNI foci, 1-5), and high PNI (PNI foci >5). Rate of cervical lymph node metastasis (LN+), 5-year disease-specific survival (DSS), and 5-year overall survival (OS) were analyzed among these groups.
RESULTS: PNI focus number independently predicted for LN+, poor DSS, and poor OS in multivariate analysis after controlling for T classification, lymphovascular invasion, differentiation, margin, and tumor thickness. The 5-year DSS demonstrated a dose-dependent decrease among the 3 groups (no PNI, 88.6%; low PNI, 75.2%; high PNI, 33.8%; P < .001). Moreover, the 5-year DSS of the high PNI group was significantly worse than that of the low PNI group.
CONCLUSION: PNI focus number can be a novel parameter for PNI quantification in early OSCC. Although optimal quantification methods still require further investigation, this study offers clear clinical support for the nerve-tumor interaction hypothesis and advocates further mechanistic research for the exploration of PNI-related treatment concepts for OSCC.

Entities:  

Keywords:  oral squamous cell carcinoma; perineural invasion; perineural invasion focus number; quantification

Mesh:

Year:  2018        PMID: 30558519     DOI: 10.1177/0194599818808510

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  5 in total

1.  Spatial and Transcriptomic Analysis of Perineural Invasion in Oral Cancer.

Authors:  Ligia B Schmitd; Cindy Perez-Pacheco; Emily L Bellile; Weisheng Wu; Keith Casper; Michelle Mierzwa; Laura S Rozek; Gregory T Wolf; Jeremy M G Taylor; Nisha J D'Silva
Journal:  Clin Cancer Res       Date:  2022-08-15       Impact factor: 13.801

Review 2.  Molecular and Cellular Mechanisms of Perineural Invasion in Oral Squamous Cell Carcinoma: Potential Targets for Therapeutic Intervention.

Authors:  Carly I Misztal; Carlos Green; Christine Mei; Rita Bhatia; Jaylou M Velez Torres; Brandon Kamrava; Seo Moon; Elizabeth Nicolli; Donald Weed; Zoukaa Sargi; Christine T Dinh
Journal:  Cancers (Basel)       Date:  2021-11-29       Impact factor: 6.639

3.  Worst Pattern of Perineural Invasion Redefines the Spatial Localization of Nerves in Oral Squamous Cell Carcinoma.

Authors:  Yong Fu; Xinwen Zhang; Zhuang Ding; Nisha Zhu; Yuxian Song; Xiaoxin Zhang; Yue Jing; Yijun Yu; Xiaofeng Huang; Lei Zhang; Qingang Hu; Yanhong Ni; Liang Ding
Journal:  Front Oncol       Date:  2021-11-29       Impact factor: 6.244

4.  The neuropeptide calcitonin gene-related peptide links perineural invasion with lymph node metastasis in oral squamous cell carcinoma.

Authors:  Yu Zhang; Mingtao Chen; Zheqi Liu; Xu Wang; Tong Ji
Journal:  BMC Cancer       Date:  2021-11-20       Impact factor: 4.430

5.  The Impact of Histopathological Features on the Prognosis of Oral Squamous Cell Carcinoma: A Comprehensive Review and Meta-Analysis.

Authors:  Eder da Silva Dolens; Mauricio Rocha Dourado; Alhadi Almangush; Tuula A Salo; Clarissa Araujo Gurgel Rocha; Sabrina Daniela da Silva; Peter A Brennan; Ricardo D Coletta
Journal:  Front Oncol       Date:  2021-11-10       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.